Drug intelligence / Profile preview

BC-101

Development stage: Phase 1
Lead developer: Bright Cell
Modality: Cell Therapies
Administration: Subcutaneous, Intradermal

Overview

BC-101 is a biological drug developed by Bright Cell, Inc. It is composed of human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension, intended for subcutaneous/intradermal injection. The drug is being investigated for the treatment of moderate to severe nasolabial fold wrinkles.

Beyond the preview

Go deeper on BC-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BC-101.

Explore the full profile